



# Amgen Inc (AMGN)

Updated February 9<sup>th</sup>, 2026, by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$374	<b>5 Year Annual Expected Total Return:</b>	6.0%	<b>Market Cap:</b>	\$201 B
<b>Fair Value Price:</b>	\$312	<b>5 Year Growth Estimate:</b>	7.0%	<b>Ex-Dividend Date:</b>	02/13/26
<b>% Fair Value:</b>	120%	<b>5 Year Valuation Multiple Estimate:</b>	-3.5%	<b>Dividend Payment Date:</b>	03/6/26
<b>Dividend Yield:</b>	2.7%	<b>5 Year Price Target</b>	\$438	<b>Years Of Dividend Growth:</b>	15
<b>Dividend Risk Score:</b>	B	<b>Sector:</b>	Health Care	<b>Rating:</b>	Hold

## Overview & Current Events

Amgen is the largest independent biotech company in the world. Amgen discovers, develops, manufactures and sells medicines that treat serious illnesses. The company focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Amgen generates about \$37 billion in annual revenues. Founded in 1980, the company began with just three employees. Today Amgen has about 28,000 employees and operates in approximately 100 countries.

On December 9<sup>th</sup>, 2025, Amgen announced that it was raising its quarterly dividend 5.9% to \$2.52.

On February 3<sup>rd</sup>, 2026, Amgen announced fourth quarter and full year earnings results for the period ending December 31<sup>st</sup>, 2025. For the quarter, revenue grew 8.8% to \$9.9 billion, which was \$440 million above estimates. Adjusted earnings-per-share of \$5.29 compared to \$5.31 in the prior year, but this was \$0.53 more than expected. For the year, revenue increased 10% to \$36.8 billion while adjusted earnings-per-share of \$21.84 compared to \$19.84 in 2024.

2025 was a year of growth for the company as 18 products produced record sales and 14 products generated at least \$1 billion in annual sales. For the quarter, growth was primarily a result of a 10% increase in volume, partially offset by a 4% decline in pricing. Prolia, which treats osteoporosis, declined 10% to \$1.1 billion due to lower selling prices and weaker volumes related to biosimilar competition. Sales erosion is expected to continue due to this competition. Repatha, which is used to control cholesterol, increased 44% to \$870 million. Amgen reduced prices for Repatha in 2018 and this has allowed the product to capture market share. Volume improved 31% while higher pricing added 8% to results. Evenity, which is used to treat osteoporosis, surged 39% to \$599 million due to increased volume. Amgen stated three quarters ago that its Phase 2 data for its injectable weight-loss drug candidate, called MariTide, revealed that the product is the first obesity treatment with monthly or less frequent dosing to demonstrate safe and effective weight loss in a Phase 2 study. Several phase 3 studies have recently been completed or are still ongoing. The company ended the quarter with \$9.1 billion of cash and cash equivalents against total debt of \$54.6 billion.

Amgen provided guidance for 2026 as well. The company expects adjusted earnings-per-share in a range of \$21.60 to \$23.00. At the midpoint, this would be a 2.1% improvement from the prior year.

## Growth on a Per-Share Basis

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2031
<b>EPS</b>	\$11.65	\$12.58	\$14.40	\$14.82	\$16.60	\$17.10	\$17.69	\$18.65	\$19.84	\$21.84	<b>\$22.30</b>	<b>\$31.28</b>
<b>DPS</b>	\$4.00	\$4.60	\$5.28	\$5.80	\$6.40	\$7.04	\$7.76	\$8.52	\$9.00	\$9.52	<b>\$10.08</b>	<b>\$14.14</b>
<b>Shares<sup>1</sup></b>	738	720	640	598	585	565	539	535	537	543	<b>543</b>	<b>530</b>

Amgen's earnings not only held up during the last recession, but grew. Over the last ten years, the company has grown earnings at a rate of 7.2% per year, though that growth has slowed to 5.5% over the last five years. We reaffirm our expected growth rate of 7% annually due to strength in new products and share repurchases, offset by the high

<sup>1</sup> Share count in millions

Disclosure: This analyst has a long position in the security discussed in this research report.



# Amgen Inc (AMGN)

Updated February 9<sup>th</sup>, 2026, by Nathan Parsh

beginning base for earnings-per-share. Amgen has been aggressively repurchasing its own shares, retiring 3.3% of outstanding shares annually since 2016. That said, share repurchases have slowed in recent years.

## Valuation Analysis

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Now	2031
Avg. P/E	13.4	13.6	13.1	13.3	13.9	13.1	14.8	15.4	13.1	15.0	16.8	14.0
Avg. Yld.	2.6%	2.7%	2.8%	3.0%	2.8%	3.1%	3.0%	3.0%	3.5%	2.9%	2.7%	3.2%

Shares of Amgen have gained \$29, or 8.4%, since our December 1<sup>st</sup>, 2025 update. Based off estimates for 2026, Amgen trades with a multiple of 16.8 times earnings. We are reaffirming our target P/E of 14 from 13.5 as this is near the medium- and long-term average price-to-earnings multiples. If shares were to revert to our target multiple by 2031, then valuation would reduce annual returns by 3.5% over this period.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2031
Payout	34%	37%	37%	39%	39%	41%	44%	46%	45%	44%	45%	45%


Amgen's profitability held up very well during the last recession. Companies in the health care sector are often recession resistant as people will seek treatment for their health issues regardless of economic conditions. The company also has a very low payout ratio that will allow it to continue to raise its dividend going forward, even in a prolonged recession.

Amgen is the largest biotech company in the world, giving it size and scale over its peers. This allows the company to reduce net selling price on products, such as with Repatha, to take market share. Another key competitive advantage Amgen has over its peers is the company's ability to bring new products to market. The company has reduced its development cycle timeline by 36 months. Amgen spent 19.8% of 2025 sales on R&D.

## Final Thoughts & Recommendation

After fourth quarter earnings results, Amgen is now projected to offer a total annual return of 6.0% through 2031, down from our previous estimate of 6.4%. Our estimated return stems from a 7% earnings growth rate and a 2.7% starting dividend yield, offset by a small headwind from multiple contraction. Once again, Amgen's newer products largely performed well during the quarter. We have raised our five-year price target \$26 to \$438 due to EPS estimates for the year. We continue to rate Amgen as a hold due to projected returns and a solid dividend risk score.

## Total Return Breakdown by Year



Disclosure: This analyst has a long position in the security discussed in this research report.



# Amgen Inc (AMGN)

Updated February 9<sup>th</sup>, 2026, by Nathan Parsh

## Income Statement Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Revenue</b>	22,683	22,784	23,768	23,261	25,246	25,987	26,092	28,010	33,232	36,751
<b>Gross Profit</b>	18,521	18,715	19,667	18,905	19,087	19,533	19,686	19,595	21,333	30,328
<b>Gross Margin</b>	81.7%	82.1%	82.7%	81.3%	75.6%	75.2%	75.4%	70.0%	64.2%	82.5%
<b>SG&amp;A Exp.</b>	5,120	4,870	5,332	5,150	5,730	5,368	5,414	6,179	7,096	7,050
<b>D&amp;A Exp.</b>	2,105	1,955	1,946	2,206	3,601	3,398	3,417	3,885	5,592	
<b>Operating Profit</b>	9,524	10,018	10,326	9,573	8,961	9,152	9,335	8,471	8,313	14,891
<b>Op. Margin</b>	42.0%	44.0%	43.4%	41.2%	35.5%	35.2%	35.8%	30.2%	25.0%	40.5%
<b>Net Profit</b>	7,722	1,979	8,394	7,842	7,264	5,893	6,552	6,717	4,090	7,711
<b>Net Margin</b>	34.0%	8.7%	35.3%	33.7%	28.8%	22.7%	25.1%	24.0%	12.3%	21.0%
<b>Free Cash Flow</b>	9,517	10,513	10,558	8,532	9,889	8,381	8,785	7,359	10,394	9,958
<b>Income Tax</b>	1,441	7,618	1,151	1,296	869	808	794	1,138	519	1,265

## Balance Sheet Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Total Assets</b>	77,626	79,954	66,416	59,707	62,948	61,165	65,121	97,154	91,839	90,586
<b>Cash &amp; Equivalents</b>	38,085	41,678	29,304	8,911	10,647	8,037	9,305	10,944	11,973	9,129
<b>Acc. Receivable</b>	3,165	3,237	3,580	4,057	4,525	4,895	5,563	7,268	6,782	9,570
<b>Inventories</b>	2,745	2,834	2,940	3,584	3,893	4,086	4,930	9,518	6,998	6,225
<b>Goodwill &amp; Int.</b>	25,030	23,370	22,142	34,116	31,276	30,072	31,609	51,270	46,336	40,956
<b>Total Liabilities</b>	47,751	54,713	53,916	50,034	53,539	54,465	61,460	90,922	85,962	81,928
<b>Accounts Payable</b>	917	1,352	1,207	1,371	1,421	1,366	1,572	1,590	1,908	20,890
<b>Long-Term Debt</b>	33,991	35,342	33,929	30,291	33,292	33,834	39,484	65,304	60,772	54,604
<b>Total Equity</b>	29,875	25,241	12,500	9,673	9,409	6,700	3,661	6,232	5,877	8,658
<b>LTD/E Ratio</b>	1.16	1.40	2.71	3.15	3.55	5.07	10.83	10.50	10.36	6.31

## Profitability & Per Share Metrics

Year	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
<b>Return on Assets</b>	10.4%	2.5%	11.5%	12.4%	11.8%	9.5%	10.4%	8.3%	4.3%	8.5%
<b>Return on Equity</b>	26.6%	7.2%	44.5%	70.7%	76.1%	73.2%	126.5%	135.8%	67.6%	106.1%
<b>ROIC</b>	12.5%	3.2%	15.7%	18.1%	17.5%	14.1%	15.6%	11.7%	5.9%	11.9%
<b>Shares Out.</b>	738	720	640	598	585	565	539	535	537	543
<b>Revenue/Share</b>	30.08	31.00	35.74	38.20	42.79	45.35	48.23	52.06	61.43	67.81
<b>FCF/Share</b>	12.62	14.30	15.88	14.01	16.76	14.63	16.24	13.68	19.21	18.37

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.